GLP-1 Client Readiness: How to Coach the 'Not Yet' Stage

If you coach anyone right now, roughly one in ten of your clients or leads is on a GLP-1 — and most of them are not ready for what you’re selling. That’s not a marketing problem. It’s a readiness problem, and treating it like a rejection is how coaches lose clients they could have kept for years.

We covered the mechanics in GLP-1 Readiness: Which of the 7 Stages Are You In? — that piece maps the whole journey from the client’s side. This one is yours. It’s about the stage coaches handle worst: “not yet.” The person on the drug who’s doing fine, or the person frozen at the pharmacy counter, and you with a pitch that lands like a sales call.

The two questions that decide everything

Readiness isn’t a mood. It’s two checkable conditions, and both have to be present:

The problem feels urgent to them right now. Not to you. Them. “This really matters to me” — said out loud, unprompted, usually after something breaks: a scare, a stall, a wardrobe failure, a lab result.

They have capacity to spend on it. Time, money, or both. A client drowning in a new job and a sick parent doesn’t have room for a coaching program no matter how motivated they sound.

Miss either one and you’re not coaching — you’re performing coaching for someone who can’t receive it. The trap is that both conditions move. The client who says “I’m fine on my own” in January can be flailing by March. The client who was too broke for your package in fall has insurance that changed in winter. Readiness is a moving target, which means the “not yet” client is future inventory, not a dead lead. Listen at every session for which condition just flipped.

Why pushing a not-ready client backfires

Every coach feels the pull: you see a client coasting on a GLP-1 with no protein plan and no lifting, and the warnings line themselves up. Don’t say them. In motivational interviewing, that instinct has a name — the “righting reflex” — and decades of research on ambivalence show it usually does the opposite of what you intend: it stiffens defenses and postpones change.

The data behind your warnings is real. Up to 40% of GLP-1 weight loss can come from lean mass, and meta-analyses of incretin therapy confirm meaningful muscle loss alongside the fat (Eisa et al., Diabetes Obes Metab, 2026 — https://pubmed.ncbi.nlm.nih.gov/41877354/). Real-world persistence data is equally blunt: a large cohort study of semaglutide in obesity found substantial first-year discontinuation (Fink et al., Front Endocrinol, 2026 — https://pubmed.ncbi.nlm.nih.gov/42582375/), and prescription-pattern analyses show most people cycle through stop-and-restart rather than staying on continuously (Lee et al., Diabetes Obes Cardiometab, 2026 — https://pubmed.ncbi.nlm.nih.gov/42920957/). Muscle protection during the drug itself is now its own research area (Prokopidis et al., Nutrients, 2026 — https://pubmed.ncbi.nlm.nih.gov/42654234/).

All true. None of it lands on a client riding high at week six. The facts aren’t wrong — the timing is.

The two “not yet” clients you’ll actually meet

The Honeymooner. Started the drug, minimal side effects, the scale is doing exactly what they wanted, and they’ve changed nothing else. Their readiness is close to zero and the correct move is celebrate, not warn. One sentence does the work: “These results are great. If you ever want to work on the layer underneath — keeping your muscle, dialing in nutrition for when the appetite comes back — I’d love to be the person you call.” Then stop. Stay visible, stay warm, and let the readiness clock run.

The Ambivalent Candidate. Doctor suggested the drug, they’ve read everything, and they’re frozen anyway. Some are scared of side effects. More than coaches expect are stuck on a moral question: am I weak if I take it? That double standard is cultural, not clinical — nobody asks if a statin means you gave up. Your job here is narrow and important: the medication decision is out of your scope of practice and belongs to the client and their provider. What you can do is help them articulate their own hesitation. The exercise that works: lay out what’s good about changing, what’s bad about changing, what’s good about staying the same, and what’s bad about staying the same. Most people have rehearsed the first two and never said the last two out loud. There’s no correct outcome — some fill the prescription, some don’t, and either way the foundational habits are the same. This is also where coaching fundamentals carry the load, whatever they decide.

When “not yet” flips to “right now”

Readiness rarely changes during good weeks. It changes when the honeymoon ends, which is also when most clients actually search for help. Three reliable flip points:

Side effects bite. Roughly half of users report nausea and a third report diarrhea in the adjustment period, and for the client living it, “normal” is cold comfort. This is the client who’s ready to hear that smaller, more frequent meals beat skipped meals, that a food log around flare-ups finds their triggers, and that severe symptoms — upper-belly pain radiating to the back, vomiting that outlasts a day, jaundice — go to their doctor immediately, not to you. Your scope is experiments (“folks who feel nauseous sometimes do better with smaller meals — want to try it this week?”), never prescriptions.

The mirror moment. The client whose weight is dropping but who can’t get off the couch without new aches. Nobody’s measuring what kind of weight is leaving. Objective baselines change this conversation faster than any lecture — a DEXA scan before and after, or failing that, a recorded squat or stair-climb test today. Numbers motivate where warnings can’t.

The money runs out. Insurance drops coverage, the job changes, the price jumps. This client is often ashamed, and the first move is naming what’s actually true: access and price were never in their control. Self-blame doesn’t survive that framing. What does survive it is the habit base — and the honest math that people who built nutrition and lifting habits during treatment hold far more of their loss after discontinuation than those who changed nothing (Kolli et al., Cureus, 2025 — https://pubmed.ncbi.nlm.nih.gov/41116804/).

What to actually do this week

Audit your language. Find one place in your consult script where you warn before you’ve been asked. Rewrite it as an invitation. Readiness responds to invitations; it armor-plates against warnings.

Build your stay-available message. One sentence, sendable, warm, zero pressure. This is your entire Honeymooner strategy, and it costs you nothing.

Get one objective baseline on every GLP-1 client you have. DEXA if you can get it; strength numbers or function tests if you can’t. You’re building the before picture you’ll wish you had in six months.

Rehearse the two-question check. Urgency — theirs, spoken. Capacity — time or money, present. If you can’t answer both yes, you just found the “not yet” stage, and now you know exactly what to do with it: stay close, plant nothing, and be the obvious call when the flip comes.

For the client’s-eye version of this same map — all seven stages and what support fits each — read the readiness stages breakdown. And if the muscle-loss side of this is your bigger worry, the protective playbook is in GLP-1 bone and muscle loss in women.

The supplement / product question

When appetite drops off a cliff, every bite has to earn its place — and coach or not, you can hand clients a realistic shopping list instead of a lecture. These three fit the “protein at every meal” playbook from the under-fueled and muscle-risk clients:

GLP-1 Protein Powder, 10g Whey Protein, Vanilla — dosed for exactly this situation: small serving, real protein, made for suppressed appetites.

GLP-1 Supplement, Gut Health, Muscle Support, Fiber Protein Shake Chocolate — covers the two jobs at once: protein plus the fiber most medicated clients fall short on.

Vital Proteins Collagen Peptides Powder, Unflavored — the stir-into-anything option when a client will reject a shake but accept a scoop in coffee.

What we still don’t know

The readiness question has a hole in the middle: no long-term trial yet shows that habit-based coaching during treatment changes post-drug outcomes. The regain data is solid, the muscle-loss data is solid, but the claim “coaching while medicated protects you after discontinuation” rests on mechanism and cohort observation, not randomized evidence of coaching itself. Anyone promising specific maintenance numbers is ahead of the data — and the two-question readiness test, useful as it is, is practice wisdom from coaching at scale, not a validated instrument. Treat your own client outcomes as the experiment.